Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Cheng

Showing results (71-80 of 120) with videos related to

Pageof 12
Sort By:
Biorxiv : the Preprint Server for Biology|August 14, 2023
Requirement of GrgA for <i>Chlamydia</i> infectious progeny production, optimal growth, and efficient plasmid maintenanceBin Lu, Yuxuan Wang, Wurihan Wurihan, et al.
American Journal of Medical Genetics. Part A|May 3, 2017
6q25.1 (TAB2) microdeletion syndrome: Congenital heart defects and cardiomyopathyAndrew Cheng, Mary Beth P Dinulos, Whitney Neufeld-Kaiser, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 28, 2016
Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyFrank A Post, Pablo Tebas, Amanda Clarke, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 13, 2016
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected AdultsJoel Gallant, Jason Brunetta, Gordon Crofoot, et al.
Journal of Clinical Pharmacology|December 31, 2013
Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatinJoseph M Custodio, Hui Wang, Jia Hao, et al.
HIV Clinical Trials|March 18, 2017
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>Frank A Post, Yazdan Yazdanpanah, Gabriel Schembri, et al.
The Lancet. HIV|August 27, 2016
Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 studyKathleen Squires, Cissy Kityo, Sally Hodder, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 19, 2016
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected AdultsGregory D Huhn, Pablo Tebas, Joel Gallant, et al.
Journal of Neural Engineering|April 16, 2015
A closed-loop compressive-sensing-based neural recording systemJie Zhang, Srinjoy Mitra, Yuanming Suo, et al.
JAMA|January 16, 2024
Nurse and Social Worker Palliative Telecare Team and Quality of Life in Patients With COPD, Heart Failure, or Interstitial Lung Disease: The ADAPT Randomized Clinical TrialDavid B Bekelman, William Feser, Brianne Morgan, et al.
Pageof 12

Showing results (71-80 of 120) with videos related to

Sort By:
Pageof 12
Biorxiv : the Preprint Server for Biology|August 14, 2023
Requirement of GrgA for <i>Chlamydia</i> infectious progeny production, optimal growth, and efficient plasmid maintenanceBin Lu, Yuxuan Wang, Wurihan Wurihan, et al.
American Journal of Medical Genetics. Part A|May 3, 2017
6q25.1 (TAB2) microdeletion syndrome: Congenital heart defects and cardiomyopathyAndrew Cheng, Mary Beth P Dinulos, Whitney Neufeld-Kaiser, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 28, 2016
Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 StudyFrank A Post, Pablo Tebas, Amanda Clarke, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 13, 2016
Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected AdultsJoel Gallant, Jason Brunetta, Gordon Crofoot, et al.
Journal of Clinical Pharmacology|December 31, 2013
Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatinJoseph M Custodio, Hui Wang, Jia Hao, et al.
HIV Clinical Trials|March 18, 2017
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>Frank A Post, Yazdan Yazdanpanah, Gabriel Schembri, et al.
The Lancet. HIV|August 27, 2016
Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 studyKathleen Squires, Cissy Kityo, Sally Hodder, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 19, 2016
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected AdultsGregory D Huhn, Pablo Tebas, Joel Gallant, et al.
Journal of Neural Engineering|April 16, 2015
A closed-loop compressive-sensing-based neural recording systemJie Zhang, Srinjoy Mitra, Yuanming Suo, et al.
JAMA|January 16, 2024
Nurse and Social Worker Palliative Telecare Team and Quality of Life in Patients With COPD, Heart Failure, or Interstitial Lung Disease: The ADAPT Randomized Clinical TrialDavid B Bekelman, William Feser, Brianne Morgan, et al.
Pageof 12